Maximizing pharmaceutical licensing opportunities


Published on

The report reviews the key trends in pharmaceutical licensing, examining deal volumes, values and structure. Therapeutic focus is also covered along with detailed profiles of the strategies of 10 leading pharmaceutical companies.

Published in: Business, News & Politics
  • Be the first to comment

  • Be the first to like this

Maximizing pharmaceutical licensing opportunities

  1. 1. Maximizing Pharmaceutical Licensing OpportunitiesPublished:June 2011No.Of Pages:153Price:US $ 3835IntroductionThe report reviews the key trends in pharmaceutical licensing, examining dealvolumes, values and structure. Therapeutic focus is also covered along withdetailed profiles of the strategies of 10 leading pharmaceutical companies. Thereport also sets out future directions for licensing and alliance activity.Features and benefits* Understand why licensing deals have become an integral part of Big Pharmastrategies, along with the future impact of these strategies.* Identify the factors that are crucial to success in the licensing sphere, and thepotential pitfalls that must be avoided.* Learn how leading players manage the licensing process, and pinpoint changes intheir approach to licensing strategy.* Track recent changes in deal-making volumes, in-licensing/out-licensing ratiosand the type of assets being targeted in major transactions.* Quantify financial commitments by licensees to external assets, and understandwhy the financial structure of licensing deals has begun to change.Browse All Pharmaceuticals Market Research ReportsHighlightsFor an increasingly risk-averse industry, licensing deals represent a moreaffordable, less risky alternative to M&A transactions. They are being used tostrengthen pipelines, manage major brand life-cycles, expand or restructureportfolios, access new technologies, and enter new geographical markets.Cancer has emerged as the therapeutic area in which most deals are being struck.Other key therapy area targets include infectious disease, CNS disorders,
  2. 2. metabolic/endocrine disease and auto-immune/inflammatory conditions. Rights toassets in these five therapy areas were traded in around two-thirds of all deals.Declared financial commitments to assets licensed by the world’s ten biggestpharmaceutical companies totaled more than US$78bn in the five-year period to2010. GSK was the biggest contributor to that figure, signing deals involving up-front fees and potential milestone payments that could exceed US$19bn.Your key questions answered* Why do a growing number of Big Pharma CEOs favor licensing and alliance dealsover M&A transactions?* How do leading multinationals structure their licensing activities, and how areapproaches changing?* What factors lie behind the recent upturn in deal-making volumes, and will theincrease be sustained?* Which therapy areas are the subject of most licensing deals?* Which companies top the Big Pharma licensing league in terms of deal volumesand financial commitments?Table Of ContentsExecutive SummaryPharmaceutical licensingPharmaceutical licensing trendsBig Pharma licensing profilesFuture trends in pharma licensingAbout the authorDisclaimerPharmaceutical licensingSummaryIntroductionMega-trends behind the pharma licensing boomAn industry in fluxLooking out, not inLicensingLicensing versus M&AGoals and targetsProcedures and approachesPharmaceutical licensing trendsSummaryIntroductionDeal volumes
  3. 3. The deal-making communityLicensing targetsDeal valuesUp-front paymentsMilestone paymentsBig Pharma licensing profilesSummaryIntroductionBig Pharma deal-making volumesFinancial commitments to in-licensed assetsLeading therapy area targetsStrategic deal making focusIn-licensing strategiesPfizerLicensing strategyLicensing activityNovartisLicensing strategyLicensing activitySanofiLicensing strategyLicensing activityMerck & Co.Licensing strategyLicensing activityGlaxoSmithKlineLicensing strategyLicensing activityRocheLicensing strategyLicensing activity
  4. 4. AstraZenecaLicensing strategyLicensing activityJohnson & JohnsonLicensing strategyLicensing activityEli LillyLicensing strategyLicensing activityAbbottLicensing strategyLicensing activityFuture trends in pharma licensingSummaryIntroductionFilling Big Pharma pipelinesAccessing novel technologiesChoice of licensing partnersHedging risks associated with pharmaceutical R&DIncreasing patient focusPortfolio restructuringBeyond pharmaceutical licensingAppendixScopeMethodologyAbout Us:ReportsnReports is an online library of over 100,000+ market research reports andin-depth market research studies & analysis of over 5000 micro markets. Weprovide 24/7 online and offline support to our customers. Get in touch with us foryour needs of market research reports.Follow us on Twitter: Facebook Page:
  5. 5. Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog